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Long periods of reduced mobility are associated with formation of blood clots in the deep veins 
of the legs, referred to as deep vein thrombosis (DVT). DVT has been noted as a large factor of 
morbidity and mortality in clinical settings as the clots can move from the legs to the lungs causing 
blockages, known as pulmonary embolisms. Preventing venous stasis has been clinically linked to 
preventing DVT formation. Venous stasis can be prevented by applying active mechanical 
compressions to the lower limbs, such as with an intermittent pneumatic compression (IPC) 
device; these devices have been clinically shown to reduce venous stasis and thereby prevent DVT 
formation. The main objectives of this thesis were to assess and improve a custom cardiac gated 
compression (CGC) system that times compressions based on an individual’s heartrate so as to 
only apply compressions during the diastolic phase of the cardiac cycle.  
A comparative performance assessment was done by measuring the central and peripheral 
hemodynamic changes induced by the use of different IPC devices (ArjoHuntleigh Flowtron 
ACS800 (Flowtron), Kendall SCD Express (SCD), Aircast Venaflow Elite (VenaFlow), and the 
custom CGC system) on 12 healthy human subjects in both seated and supine positions. The four 
selected compression devices had similar applied pressure levels, but dramatically different 
application profiles with regards to timing and method of application (e.g., single uniform bladder 
versus sequential inflation from ankle to knee).  In addition, the compression systems were 
delineated by “smart” versus fixed timing, with two devices employing physiological measures to 
adjust when compression occurred (SCD: slow inflation based on vascular refill time; CGC: rapid 
inflation based on cardiac gating), and two inflating at fixed intervals (VenaFlow: rapid inflation; 
Flowtron: slow inflation). The devices were tested for ten minutes while heart rate, stroke volume, 
cardiac output, calf muscle oxygenation, and femoral venous and superficial femoral arterial 
velocities measures were collected. From the femoral venous velocities, the velocity per minute, 
peak velocity during the compression period, and the displacement per compression and per hour 
were used as performance metrics.  
With respect to the peak velocity the VenaFlow resulted in higher results than all other devices; 
likely due to its rapid inflation characteristics and the frequency of compressions allowing pooling 
to occur in the legs. However, in the performance metric of average displacement per compression 
the Flowtron and SCD resulted in the greatest displacements; likely because of the devices’ longer 
inflation periods resulting in a longer increase in venous velocity per compression. However, this 
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measure does not account for the frequency of compressions unlike the displacement per hour 
measurement; the displacement of venous blood per hour resulted in the CGC device performing 
as well as the slow inflation devices during supine and resulted in greater displacement than all 
other devices in the seated position. The CGC also resulted in a sustained increase on the systemic 
and peripheral hemodynamics in the measures of SV when seated, and arterial velocity and muscle 
oxygenation when seated and supine; this can potentially be attributed to the device’s cardiac 
gating and resultant compression frequency. Interestedly, the Flowtron and SCD’s behaviour in 
most measures taken at steady state were not significantly different despite the “smart” timing 
employed by the SCD. 
The current timing mechanism of the CGC device is based on the previous R-R interval of the 
electrocardiograph (ECG) trace and a fixed pulse wave transit time. Due to heart rate variability 
and changes in vascular conductance, the compressions of the CGC could be more reliably 
triggered based on a local measurement of the pulse arrival. To address this need, a custom pulse 
sensor that uses photoplethysmography (PPG) to detect the pulse in the lower limb was developed. 
Key problems that impact wearable PPG sensor performance are motion, the power requirements 
of the LEDs and the ability to work on darker skin pigmentations.  
The sensor design was done with the primary objective of reliably and robustly detecting the 
pulse wave arrival regardless of skin tone or application location, and the secondary objective of 
maximizing the battery life of the sensor for future potential applications in wearable technologies. 
The developed sensor is reflectance-based and employs 6 independently controlled light emitting 
diodes (LEDs) surrounding a single photodiode. The independent control enables the “best” LED 
configuration to be selected through an in situ calibration cycle that results in the strongest signal 
at the lowest power setting required for different skin pigmentations in non-motion and motion 
conditions. The shin, in comparison to the foot and ankle, was determined as the best measurement 
location in terms of motion resistance and low power requirements. Furthermore, the calibration 
cycle proved to effectively adapt to the underlying physiology and find the LED configuration that 
resulted in the strongest pulse signal at the lowest possible power setting for each individual. 
Therefore, as the PPG sensor was proven to work effectively from the lower limb, further 
improvement to the timing of compressions for the CGC device may be possible through the 
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1.1 Introduction and Background 
Venous thromboembolism (VTE) is a vascular disease that is made up of two components, 
deep vein thrombosis (DVT) and pulmonary embolisms (PE) [1], [2]. DVT occurs when blood 
clots form in the deep veins of the leg [3], [4]. PE is primarily the result of clots moving from the 
deep veins of the legs to the lungs, which can cause blockages in the lungs and is a major cause of 
morbidity and mortality in intensive care units [4], [5]; 10% of all PE cases are fatal within the 
first hour of symptoms appearing for the patient [4], [5]. DVT prevention is key to reducing 
subsequent complications and the incidence of fatalities.  
Prevention treatments aim to address one or more of Virchow’s triad of factors (i.e. venous 
stasis, vessel damage, and hypercoagulability) that cause DVT [6]–[10]. Based on clinical results, 
hospitalized patients, particularly post-surgical patients, have a higher risk for DVT due to venous 
stasis exacerbated by their reduced mobility [1], [7], [11]–[13]. The risk of DVT increases with 
both age and the length of the surgery [14]. It is estimated that 20% of patients that undergo a 
major surgical procedure will develop DVT; however, in patients that undergo orthopedic surgery 
the risk of DVT is particularly prevalent, as an estimated 40% will develop DVT [15].  
There are two broadly classified preventative treatments for DVT; pharmacological solutions, 
typically in the form of anti-coagulants, and external prophylaxes that encourage venous flow 
through mechanical limb compression. External compression can be applied with intermittent 
pneumatic compression (IPC) devices which have been proven to effectively lower the risk of 
DVT formation [6], [9]–[11], [15]–[18], while also having a lower associated risk of bleeding 
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complications than pharmacological treatments [3], [8], [10]–[12]. IPC devices work by inflated 
cuffs placed on the lower leg to apply compressions, thereby forcing the venous blood to move out 
of the leg. While IPC devices are effective at lowering the risk of DVT formation, is it still 
unknown what is the best timing profile for the devices with respect to the inflation rate of the 
cuffs, and the timing algorithm used to determine both when to trigger compressions and the 
frequency of compressions. By determining the effects of different timing profiles on the 
peripheral and central hemodynamics it could be possible to determine the most effective profile; 
this could improve the ability of the devices to prevent DVT.  
1.2 Overview of the Circulatory System 
 The circulatory system is comprised of two subsystems, the pulmonary and systemic 
circulations, as shown in Fig. 1; this section herein will summarize from Silverthorn (2010) [20]. 
The pulmonary system sends deoxygenated blood from the right ventricle of the heart through the 
pulmonary arteries to the lungs, where the blood is oxygenated. The oxygenated blood returns 
through the pulmonary veins to the left atrium of the heart. In the systemic circulation, the more 
oxygenated blood is pumped from the left ventricle of the heart; the arteries then carry the 
oxygenated blood from the heart throughout the body. The veins work to return deoxygenated 
blood from the tissue to the heart. While the venous blood is not completely devoid of oxygen, it 




Fig. 1 Circulation of blood throughout the body through arteries and veins [20]. 
The flow of blood in the arteries is driven by the pressure wave from contraction of the left 
ventricle of the heart; due to the friction between the fluid and the vessel walls the pressure wave 
decreases over distance. This pressure wave disappears within the capillaries, as such the blood 
within the veins is not pulsatile. The veins are more compliant as they have thinner walls consisting 
of less elastic tissue than arteries, as such they are able to expand to accommodate venous pooling. 
The venous system serves as a volume reservoir for the body due to the larger diameter and more 
numerous quantity of veins in comparison to arteries.   
 A key contributor to the circulation of blood in the lower limbs is the muscle pump. The muscle 
pump functions as a “second heart” within the lower limbs, working to pump venous blood back 
to the heart. During ambulation, the muscles in the calf contract, applying force on the compliant 
veins and pushing the venous blood out of the limb, see Fig. 2. As the flow in the veins is not 




Fig. 2 Muscle pump's affect on veins [20]. 
The muscle pump has an effect on the pressure gradient within the circulatory system. The 
difference in pressure between the arteries and veins in the circulatory system is known as the 
arterial-venous pressure gradient; this difference is due to the high pressure that originates when 
arterial blood is pumped out of the heart and the decrease in pressure as the blood moves further 
from the heart, see Fig. 3. The muscle pump-induced venous return from the lower limbs increases 
this pressure gradient, and the arterial blood movement toward the lower pressure area in the limb, 
thereby improving the circulation [20], [21]. When a person is sedentary the muscle pump is not 
able to contribute to the venous return resulting in the venous blood pooling in the lower limb. 
This venous stasis in the legs is one of the factors that leads to DVT formation. 
 
Fig. 3 Pressure gradient throughout the circulatory system [20]. 
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1.3 Venous Thrombosis Initiation and Progression 
Blood coagulation in the vascular system can be beneficial or dangerous depending on the 
circumstances surrounding the clot formation. The hemostatic system is responsible for clot 
formation [3], [20]. Clot formation is important when a vascular injury has occurred for the 
prevention of excessive bleeding and the clots dissolve after the injury has healed [3], [20]. 
However, the mechanisms for clot formation under normal circumstances are also involved in 
DVT creation in the absence of vessel injury. The composition of arterial and venous clots are 
different, with clots formed within veins primarily composed of fibrin, trapped red blood cells and 
platelets [3], [22], [23].  
What causes the initiation of venous thrombosis is not fully known, however there are three 
primary factors that are known to influence DVT formation, namely hypercoagulability, vessel 
damage, and venous stasis [3]. Hypercoagulability is a condition where the blood is more prone to 
forming clots, this can be due to lower fibrinolytic activity [24]; fibrinolysis is the dissolution of 
fibrin by enzymes to remove clots [20]. Vessel damage can influence DVT if the body does not 
have a proper balance of the hemostatic response to an injury and results in blood clots forming 
on undamaged walls of the blood vessels [20]. Venous stasis can affect clot formation as it is 
hypothesized that the flow in the vessels has an effect on the formation and that reduced venous 
flow can be part of what triggers coagulation to stabilize the clot formation [3]. 
1.4 DVT Treatments 
There are two key methods of DVT prophylaxis; anticoagulant drugs and mechanical 
compression to the lower limbs [3], [8], [11], [12]. Anticoagulant drugs are designed to treat the 
hypercoagulability factor and have been found to significantly lower the rate of DVT in clinical 
settings [14], [16]. Mechanical compression treats the venous stasis factor and can be applied 
through active or passive compression; both methods have been shown to lower the risk of DVT 
[14], [25]. Whereas passive compression is applied through the use of compression stockings, 
which work to mechanically limit the diameter of the deep veins thereby limiting the venous 
pooling that can occur [25], [26], active compression is applied through the use of devices capable 
of intermittently applying compressions to the lower limb. The active compression empties the 
pooled venous blood, which results in a change to the arterial-venous pressure gradient, thereby 
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increasing arterial inflow and overall peripheral circulation [21], [27]–[30]. Active compression 
systems have been shown to produce a similar effect to a muscle pump on the venous system in 
order to improve circulation in the lower limb [15], [16].  
Both anticoagulants and mechanical compression methods have been proven to be effective, 
with combination treatments being the most effective [16], [25]. However, when used separately, 
anticoagulants and active compression have proven more effective than passive compression at 
DVT prevention [14], [25]. Drawbacks have been identified for each mitigation method that 
impact implementation and/or treatment outcome. A problem typically encountered with passive 
compression is poor fitting of the compression stockings, as this dramatically affects the pressure 
applied to the limb [25], [26]. A key challenge faced with prescribed active compression is the 
patient compliance; the duration and frequency of device use impacts the efficiency of DVT 
prevention [15]–[17], [25]. For example, patients that used an active compression device for more 
than six hours a day were at a significantly lower risk of forming venous blood clots than patients 
who used the device for less than six hours a day following their orthopaedic procedures [16]. 
Anticoagulants are associated with an increased risk of bleeding, which limits their prescription to 
particular patient populations [3], [8], [10]–[12]. Active compression has been identified as a 
preferred alternative treatment method to passive compression due to the increased effectiveness 
for DVT prevention and in cases where the bleeding complications eliminate anticoagulants 
treatment methods from consideration. 
1.4.1 Active Mechanical Compression 
Active mechanical compression is typically achieved through the use of IPC devices, see Fig. 
4A, which have been proven to be an effective method of DVT prevention [6], [9]–[11], [15]–[18].  
The cuffs of the device are placed on the lower limbs and inflated to apply compression to the 
limb, see Fig. 4B; thereby reducing venous stasis in the lower limb and preventing DVT formation 
[15], [31]–[33].  
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Fig. 4 Sample IPC device (A – Pump and tubing [34], B – Application of cuffs [35]) 
The inflation rate and duration of the compressions applied with the cuffs varies with each 
manufacturer but typically fall into two categories; rapid inflation with a short period of 
compressions or slow inflation and a longer period of compressions. It is still debated as to which 
device is more efficient at DVT prevention [6], [10], [15], [24]. Additionally, the frequency of 
compressions applied by the IPC devices also varies between devices, but is regulated by either 
fixed or “smart” timing algorithms. Fixed timing algorithms initiate compressions at set intervals 
that is not dictated by external signal measurements. “Smart” timing algorithms trigger 
compressions based on signal feedback from physiological measurements, which customizes the 
compression timing to an individual. Inflation rate and compression timing have been suggested 
to influence physiological response to treatment [9], [12], [18], [28], [36], [37]. 
1.4.2 Physiological Measurements 
IPC device performance related to DVT prevention is typically assessed based on compression 
induced changes in peripheral venous hemodynamics [12], [15], [24], [36]–[38]. Specifically, the 
metrics of peak and  average venous velocity during the compression period are used to quantify 
performance as these are taken to be representative of the device’s ability to empty the venous 
blood from the lower limb and prevent venous stasis [12], [15], [24], [36]–[38]. Devices with 
compressions that consist of rapid inflation over short durations typically result in higher peak 
velocities while, devices which use profiles of slow inflation and have longer durations of 




[24]. However, if is still debated whether peak velocity or average velocity is a better indication 
of DVT prevention [6], [10], [15], [24]. 
Morris et al. (2004) and Malone et al. (1999) noted that though there are flow differences that 
result from the inflation rate of the devices there has not been conclusive clinical proof as to 
whether a longer duration of increased velocity or a higher peak velocities is more effective at 
preventing DVT formation [6], [24]. Kakkos et al. (2005) and Warwick et al. (2008) similarly 
admit that it is unknown whether higher peak velocities or longer increases in velocity is the better 
mark of performance; however, both have different hypotheses as to which is the more effective 
measure [10], [15]. Kakkos et al. (2005)  hypothesizes that the measure of longer periods of 
increased velocity is the better, as this might be an indication of reduced venous stasis in the valve 
pockets of the deep veins [10]. In contrast, Warwick et al. (2008) argue in favour of peak velocity, 
stating that it is a better indication of the IPC device’s ability to mimic the turbulent, high velocity 
peripheral venous effects caused by ambulation [15]. However, it is also possible that there is a 
larger systemic response that cannot be fully studied by collecting only one measure of the 
peripheral hemodynamics. 
1.4.3 “Smart” Timed IPC Devices  
The majority of commercial devices use fixed timing, however there has been evidence that 
the use of “smart” timing algorithms may comparatively improve the performance of the IPC 
devices with respect to increased peripheral circulation [36]–[38]. For example, a device that times 
compressions based on the individual’s venous refill rate has been shown to result in a longer 
duration of increased venous flow caused by compressions compared to similar devices that used 
slow inflation and longer periods of compression [36], [38], and a device that used a rapid inflation 
and shorter duration of compressions [36], [37].  
The pulse-synchronized air-massage (PS-AM) device (Advance Co, Tokyo, Japan) triggers 
during the diastolic phase of the cardiac cycle, and has been proven to significantly increase the 
arterial blood flow in comparison to baseline measurements with no compressions applied [39]. 
Preliminary tests of the PS-AM device have also demonstrated significantly increased arterial 
blood flow when timed to the diastolic phase of the cardiac cycle, in comparison to fixed timing 
of the compressions at one second intervals [39]. 
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A new cardiac gated compression (CGC) IPC device has been developed with a “smart” timing 
algorithm that utilizes prospective ECG gating technique and fixed pulse wave transit time from 
the heart to the lower limb compression location as inputs to determine when compression should 
be triggered. In addition, compression is initiated and completed during the local diastolic phase 
of the lower limb within a single cardiac cycle. The compression timing within the current cardiac 
cycle is based on the duration of the previous cardiac cycle, as such can vary from one cardiac 
cycle to the next depending on changes in heart rate. The CGC device has been shown to 
significantly increase both arterial and venous velocities during and after mild exercise [40].  
The PS-AM device and the CGC device vary with respect to the method of detecting the cardiac 
cycle. The CGC device uses an ECG trace, whereas the PS-AM uses photoplethysmography (PPG) 
to detect the pulse from either the ear lobe or the fingers [39]. Furthermore, the CGC device 
completes a single compression cycle within one cardiac cycle, whereas the PS-AM requires four 
cardiac cycles to complete the compression cycle [39]. While the PS-AM device varies from the 
CGC device with respect to several design considerations, the results suggest that this form of 
“smart” timing will be efficient at increasing peripheral circulation.  
1.5 Peripheral Sensor Considerations for “Smart” Compression 
Timing 
 Effectively timing a “smart” compression system requires real-time acquisition and processing 
of the controlling physiological signal.  This can be heart rate or pulse arrival time in the case of 
cardiac-gated compression systems, or leg circumference in the case of venous refill time-based 
systems. The time-scale of the latter is much longer than that of the former, which requires much 
higher data rates and processing times. This section focuses on technologies that can be used for 
detecting the heartbeat, or local blood arrival time, for cardiac gated compression systems. 
Specifically discussed are sensors that use optical sensing, mechanical pressure, and bio-
impedance. The choice of which sensor to use depends on the requirements of a given system. For 
cardiac gated compression systems, the primary concern is the reliability of pulse detection from 
the lower limb, compact size, and ease of use.  
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1.5.1 Photoplethysmography (PPG) 
PPG is an optical technology that works by transmitting light into biological tissue and 
measuring the change in light intensity reflected back [41]. The light reflected back will contain 
an AC component to the signal which corresponds to the arterial blood volume changes and 
thereby the person’s cardiac cycle [41]. The peaks of the PPG waveform have been proven to the 
correspond to the RR peaks of the ECG trace; proving that this method is capable of accurate pulse 
rate detection [41]–[43]. This method has also been shown previously to produce a measurable 
pulse signal from the lower limb and has been used as an monitoring tool for lower limb circulation 
[44]–[46]. Specifically, the pulse signal has been found from the calf [44], the anterior thigh region 
[45], and the anterior surface of the lower leg [46]. Based on the various regions on the leg that 
the PPG pulse sensor was able to detect the pulse it has been shown that this type of sensor does 
not require a location directly above a shallow artery in order to find the pulse signal. Furthermore, 
this method is commonly found in wearable HR monitoring technology due to its small profile and 
simplicity [47], [48]. However, key problems facing PPG technology are the sensitivity to both 
motion artifacts [41], [49] and skin pigmentations [50], [51]. 
1.5.2 Mechanical Pressure 
The sensor that was based on mechanical pressure changes used a condenser microphone as 
the sensing component. A condenser microphone works as a pressure sensor to detect the pulse 
wave from the surface of the skin [52], [53]. The sensor can be small in size but have a high signal 
quality; as the diaphragm usually has a very small mass such that the sensor is largely immune to 
whole body movements [53]. The pulse signal detected by this type of sensor has been proven to 
correspond to an ECG trace when measured from the wrist [53]. Furthermore, measurements have 
been taken from the wrist, neck, forehead, inside and behind the ear [53]. However, these are all 
sites of relatively shallow arteries, it is unknown if this type of sensor could sense the pulse wave 
from deeper vessels of the lower limb. It is therefore possible that this sensor may be very sensitive 
to the measurement location making it harder to use across individuals. 
1.5.3 Bio-impedance 
Bio-impedance sensors work by placing pairs of emitter and receiver electrodes around an area 
of the body; the sensor will then emit an imperceptible electric current into the body and measuring 
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the change in impedance between the receiver electrodes [54]. This change in impedance if caused 
by fluid shifts; the sensor is able to detect the cyclic blood shifts caused by the cardiac cycle [54]. 
This method is typically used on the torso but has been shown to accurate detect the pulse signal 
from the forearm when compared to commercial pulse detection units [55]. This type of sensor is 
also very sensitive to motion artifacts [54], [55]. Furthermore, as multiple electrodes are required 
for the sensor to properly function this sensor will have a larger measurement area than the other 
two sensors considered. Finally, as the electrode placement can impact the signal quality [55], this 
sensor would require some training for individuals to use it properly. 
1.6 Thesis Objectives 
The focus of this thesis is on characterization and advancement of a novel cardiac gated 
compression system. This overall project is decomposed into two research directions, which this 
thesis attempts to advance: (1) comparing the system performance to existing commercial IPC 
devices, and (2) development of a new robust PPG sensor for detecting local pulse arrival for 
timing the compression system.  
1.6.1 Study 1 Objectives 
Component (1) is a comparative performance study between a custom cardiac-gated 
compression system developed in Mechanical and Mechatronics Engineering and Kinesiology at 
the University of Waterloo and existing commercial devices. More generally, this study aims to 
determine if IPC devices that use “smart” timing perform better than those with fixed timing and 
to test whether one form of “smart” timing is more efficient. To characterize the performance, the 
traditional metrics of peak venous velocity and average augmented velocity during the inflation 
period will be investigated. However, in order to have a better comparison of the effects of the IPC 
devices on systemic and peripheral hemodynamics; measurements of venous velocity, arterial 
velocity, stroke volume, heart rate, and muscle oxygenation were used to compare the performance 
of the devices.  
1.6.2 Study 2 Objectives 
For component (2), the primary objective is to develop a sensor and calibration cycle that would 
enable online determination of the optimal LED configuration and lowest possible intensity for an 
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individual’s skin pigmentation and detection location. The primary focus is reliability and data 
fidelity, with a secondary consideration of optimizing battery life. Furthermore, the location on the 
lower limb that is most resistant to movement will be investigated to enable use of the sensor 
during rest and motion conditions. 
1.7 Organization  
This thesis is broken into three chapters. Chapter 2.0 covers the research that quantifies the 
performance of the CGC device in comparison to three other commercial IPC devices. Chapter 3.0 
covers the results of the research into the performance of the pulse sensor designed for the 
periphery and its unique calibration cycle. Chapter 4.0 discusses the overarching results, 

















Intermittent pneumatic compression (IPC) is a proven mitigation strategy for deep vein 
thrombosis (DVT) formation in at-risk populations [11], [16]–[18]. Functionally, IPC emulates the 
muscle pump by mechanically compressing the veins, typically with inflatable air bladders, which 
squeezes the blood out of the venous system, thus reducing venous stasis and improving venous 
return to the heart [15], [31], [32], [56]. While similar in desired function, IPC devices vary with 
respect to key actuation parameters, including: the number and distribution of air bladders; the 
frequency and sequence of compressions (e.g., uniform versus graded/sequential compression); 
inflation rate and duration; and the applied pressure levels.  
Studies that aim to quantify the performance of IPC devices with respect to DVT prevention 
typically use only peripheral venous hemodynamic to comment on the performance of the device, 
with peak venous velocity and average flow during the compression period being the most 
common measures [12], [15], [24], [25], [37], [57]. Direct comparison studies between devices 
have found that multi-bladder systems that are sequentially inflated and/or have graded pressure 
from ankle to calf induce higher venous velocities than uniform pressure (typically single bladder) 
devices [31], [58], [59]. Inflation rate has also been shown to impact venous velocity, with rapid 
inflation devices eliciting higher peak venous flow rates, while slow inflation devices which inflate 
over a longer duration elicit longer periods of increased venous flow rates [9], [12], [15], [24], 
[37], [57]. From a clinical perspective, it is still a matter of some debate whether peak venous flow 
rate or duration of increased venous flow is a more important for mitigating DVT formation [6], 
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[10], [15], [24], though both measures indicate a reduction in venous stasis, which is directly 
correlated to clot formation.  
Pressure and timing are both key factors in term of IPC performance. It has been shown that 
higher pressures result in greater emptying of the veins in the lower limbs [60]; however the timing 
of the compressions affects when this pressure is applied and how effectively it can be used. 
Though not common in commercial compression devices, there is evidence suggesting that timing 
algorithms based upon physiological measures of the user can further enhance peripheral 
circulation [10], [37], [57], [61]. The Kendall SCD Express estimates the venous refill time by 
actively measuring the calf circumference of the user during a calibration period and uses this 
measure to adjust the compression frequency [10], [37], [57], [61]. This “smart” timing algorithm 
has been shown to result in a longer duration of increased venous flow caused by compressions 
compared to similar devices that used slow inflation and longer periods of compression [38], [57], 
and a device that used a rapid inflation and shorter duration of compressions [37], [57]. Another 
form of “smart” timing uses photoplethysmography (PPG) to detect the pulse from either the ear 
lobe or the fingers and triggers compressions to begin during the diastolic phase of the heartbeat 
and completes a full compression cycle over four cardiac cycles [39]. This form of “smart” timing 
has been shown to significantly increased peripheral arterial blood flow when timed to the diastolic 
phase of the cardiac cycle, in comparison to fixed timing of the compressions at one second 
intervals [39]. 
Recently, we have developed and tested a rapid inflation/duration cardiac gated compression 
(CGC) device that times compressions to the heart beat detected via electrocardiography (ECG) 
and completes a full compression cycle within one heartbeat. We have demonstrated that this 
system significantly increases arterial inflow velocity and venous return velocity during and after 
mild exercise [40]. In this manuscript we aim to evaluate the performance of CGC versus other 
established timing modalities employed by commercial IPC systems. Specifically, we compare 
devices employing fixed versus “smart” timing, and slow versus rapid inflation rates to assess the 
impact of timing modality on peripheral and systemic circulation enhancement. We hypothesize 
that the systems employing “smart” timing will outperform the fixed frequency devices. We 
further hypothesize that the new CGC system will result in greater sustained circulation 
enhancement than the venous refill-based system.  
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2.2 Methods and Materials 
2.2.1 Compression Systems 
The study included four IPC devices with different compression timing profiles in order to 
compare the impact of this parameter on the central and peripheral hemodynamics. The key 
differences between the devices are the timing profiles and cuff segmentation.  The characteristics 
of each device are summarized in Table 1. The ArjoHuntleigh Flowtron ACS800 (Flowtron) and 
the Kendall SCD Express (SCD) are both slow inflation devices while the Aircast VenaFlow Elite 
(VenaFlow) and cardiac gated compression (CGC) device are both rapid inflation devices. The 
Flowtron and the VenaFlow have a simpler, fixed frequency of compressions. Both the SCD and 
the CGC use different forms of “smart” timing to deliver compressions at a frequency that adapts 
to the individual. The SCD consistently applies pressure for 11 seconds however, the time between 
compressions varies between 20 to 60 seconds depending a calculated vein refill time [10]. The 
CGC device is a custom in-house developed system with a compression frequency dependent on 
the participant’s heart rate and cuff inflation occurring during the local peripheral diastolic phase 
of each cardiac cycle.  
Table 1: IPC Device Compression Profiles and Cuff Designs.  
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A timing diagram is provided in Fig. 5 to help visualize the timing profile of each device. The 
duration of time the compressions for the left and right leg are applied in shown within a one-
minute time span. It is assumed the left leg is the first to be compressed for the commercial devices. 
Furthermore, the compression period for the CGC device is too small to be easily noted however, 
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compressions to both the left and right legs occur between each of the vertical lines on the timeline. 
For plotting purposes, it is assumed the individual has a heartrate of 60 beats per minute (bpm) for 
the CGC device and has the minimum vascular refill time possible for the SCD. 
 
Fig. 5 Timing profiles showing compression duration and frequency for each IPC device in one minute 
In order to remove the added variability of the effects of applied pressure, all devices were set 
to apply pressure within the range of 40-55 mmHg. Furthermore, all devices applied active 
compression to the lower limb with calf length cuffs. 
2.2.2 Participants 
The study participants included 12 healthy volunteers (6 males, 6 females) of age 26 ± 5.4 
years with sedentary to moderate exercise lifestyles participated in the study.  The average height 
and weights of the participants were 172.6 ± 8.3 cm and 70.0 ± 8.4 kg, respectively. 
Individuals who had been diagnosed with or were currently being treated for cardiopulmonary 
conditions, skin sensitivities, or peripheral vascular sensitivity were excluded from participation 
in this study. Participants were asked to refrain from consuming alcohol, caffeinated beverages, 
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and from engaging in vigorous exercise during the 24-hour period prior to testing. Additionally, 
the participants were requested to refrain from consuming a large meal within the 2 hours of the 
testing period. 
The experimental protocol for this study received clearance from the University of Waterloo 
Research Ethics Committee (ORE #21877) and conformed to the Declaration of Helsinki. 
2.2.3 Experimental Protocol 
The study was divided into two protocols, each occurring on separate days at approximately 
the same time of day. In each protocol, the participant was either seated in an upright position or 
supine with their legs slightly elevated. These postures were chosen  to characterize the 
performance of the devices in positions typically occupied during prescribed use [16], [24]. The 
order of the protocols and the order in which the devices were tested were randomized between 
participants. For both body positions, the protocol was comprised of a one-minute baseline prior 
to the application of compression, a ten-minute compression period, and five-minute recovery 
period. All participants remained in the respective test body position for the duration of the 
protocol and asked to remain still to reduce data contamination from motion. 
2.2.4 Data Collection 
Data were collected continuously during the protocol with three time periods used to quantify 
the performance of the IPC devices; the baseline, the transient response, and the steady state 
response to compressions. The baseline prior to the start of compressions is used as a reference 
period to assess the transient and steady state response to compression. The transient response was 
evaluated based on the average of the first minute of compressions, spanning the first compression 
of the fixed timing devices and the first several compressions of the “smart” timing IPC devices 
depending on the individual’s heart rate and vascular refill time. The steady state condition 
achieved with the application of compression devices was taken as the average response over the 
three last compression periods for the metrics of peak venous velocity and average venous 
displacement during compression. The steady state condition for all other measures was taken as 
the average response over the last minute of compression.  
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A standard 3-lead chest electrocardiogram (ECG; Pilot 9200, Colin Medical Instruments, San 
Antonio, TX) was used for heart rate (HR) measurements, which were recorded at a sampling 
frequency of 1kHz. A photoplethysmography cuff (Finometer, Finapres Medical Systems, 
Amsterdam, Netherlands) was placed on the middle finger of the right hand to continuously 
monitor the local arterial pressure wave. The cardiac stroke volume (SV) of the participant was 
determined from the analysis of the pressure wave using the Modelflow ® algorithm (Finapres 
Medical Systems, Amsterdam, Netherlands). Data were collected at a sampling frequency of 1 
kHz.  
A 4-MHz Doppler ultrasound probe (WAKIe, Atys medical, France) was used to continuously 
record the venous velocity from the femoral vein in the right leg. Venous velocity data were 
collected at a sampling frequency of 200 Hz. The peak venous velocity and the average volume of 
venous blood ejected during the last three compression cycles were used to quantify the IPC 
devices’ performance which is on par with published metrics for IPC systems [9], [10], [12], [15], 
[24], [37], [57]. The average volume measures are used to estimate the total venous displacement 
resulting from compression over an hour [10], [37], [57]. These metrics were calculated with the 
volume measures being replaced with displacement to account for the lack of venous diameters. 
This study also examined the average venous velocity over the first and last minute to determine 
the average velocity in the limb beyond just the compression period. HR, SV, and venous velocity 
measurements were concurrently acquired using a Powerlab data acquisition system (Powerlab, 
ADInstruments, Colorado Springs, Colorado, USA).  
Echo Doppler ultrasound (Mindray M5, Shenzen Mindray Bio-medical Electronics, Shenzen, 
China) was used to record the arterial velocity from the superficial femoral artery (SFA) in the left 
leg at the set three time points of interest during the testing. Arterial velocity data were collected 
at a sampling frequency of 125 Hz. A Near-Infrared Spectroscopy (NIRS) probe (PortaLite, Artinis 
Medical Systems B.V., Elst, The Netherlands) was placed on the back of the left calf over the 
lateral head of the gastrocnemius muscle to continuously measure the muscle oxygenation. The 
NIRS data were separated into measures of the concentrations of the oxygenated hemoglobin 
(O2Hb), deoxygenated hemoglobin (HHb), and total hemoglobin (tHb), which were collected at 
three depths; however, only the measures at the deepest penetration depth were analyzed to 
compare the changes in hemoglobin concentrations caused by compressions. All NIRS 
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measurements were collected at a sampling frequency of 50 Hz. NIRS measurements were 
collected on eleven of the twelve study participants. 
2.2.5 Statistical Analysis 
Both the supine and seated data underwent the same statistical analysis. For each of the 
physiological measurements, mixed effects models were used to model the measurement response 
based on the fixed effects of time and device, and the random effect of the participants. The 
quantile-quantile (QQ) plots of the data sets for this study showed that the models were good fits 
for the data. However, there was minor divergence from the tails of the QQ plots for the arterial 
velocity, the O2Hb concentration and the venous peak velocity data sets from the seated protocol. 
The initial level of significance used for the statistical analysis was an alpha value of 0.05. The 
Bonferroni method was used to adjust the level of significance to protect against multiple 
comparison errors [62]. Hypothesis tests were conducted with pairwise t-tests.  
The device factor used six pairs of comparisons to compare each of the four devices to one 
another. The peak velocity and displacement measurements had a simplified time factor, as such 
the Bonferroni adjusted level of significance of the data becomes p<0.008. For all other measures 
the time factor used two paired comparisons to compare each of the time points during 
compression (first minute of compressions, and last minute of compressions) to the baseline 
values.  Due to an interaction effect between the fixed factors the Bonferroni adjusted level of 
significance of the data becomes p<0.004.  
2.3 Results 
2.3.1 Central Hemodynamics 
Table 2 and Error! Reference source not found. presents pooled heart rate (HR), stroke 
volume (SV), and cardiac output (CO) data for all devices during baseline, the first minute of 
compressions, considered the transient state, and the last minute of compression, considered the 
steady state configuration, for the seated and supine protocols respectively. CGC showed 
significantly increased SV maintained throughout the compression period, as well as a slight 
decrease in HR during steady state. There was a trend towards increased SV in steady state for the 
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Flowtron device. However, all three commercial devices demonstrated significantly lower SV than 
the CGC device for the duration of compression. Furthermore, CO was increased during the 
transient stage for the CGC device only; adaptation occurred by the steady state time point such 
the SV increase was compensated by a HR decrease, resulting in only a trend towards increased 
CO (p=0.1). The SCD and Flowtron devices exhibited lower CO than the CGC device during the 
transient phase, while the VenaFlow and the SCD were lower and significantly lower, respectively, 
from the CGC in the steady state. 
Table 2: Central hemodynamic results throughout the seated compression protocol. Results are shown (mean ± std) 
for all compression devices at the baseline (1 minute before the start of compressions), the transient state (first 
minute of compressions), and the steady state (last minute of compressions). Significant interaction effects are 
denoted as follows: *Results are different (p<0.05) from baseline; **Results are significantly different (p<0.004) 
from baseline; #Results are different (p<0.05) from CGC at the corresponding time point; ##Results are 
significantly different (p<0.004) from CGC at the corresponding time point. 
 Baseline First Minute Last Minute 
Heart Rate (bpm)    
 CGC 67.9 ± 10.6 66.8 ± 9.5 65.3 ± 9.4 * 
 Flowtron 69.6 ± 11.9 69.1 ± 10.7 68.3 ± 9.6 # 
 SCD 69.5 ± 12.5 68.9 ± 11.0 67.3 ± 9.8 
 VenaFlow 68.4 ± 10.9 66.6 ± 9.4 66.7 ± 8.6 
Stroke Volume (mL)    
 CGC 81.3 ± 19.8 88.1 ± 19.5 ** 87.7 ± 19.3 ** 
 Flowtron 75.9 ± 21.9 77.3 ± 20.1 ## 79.2 ± 22.8 * ## 
 SCD 76.5 ± 23.1 78.0 ± 22.2 ## 76.2 ± 22.2 ## 
 VenaFlow 78.2 ± 16.6 81.1 ± 17.2 ## 79.3 ± 20.8 ## 
Cardiac Output (L/min)   
 CGC 5.4 ± 0.9 5.8 ± 1.1 * 5.7 ± 1.0 
 Flowtron 5.2 ± 1.3 5.3 ± 1.3 # 5.4 ± 1.5 
 SCD 5.2 ± 1.5 5.3 ± 1.3 # 5.1 ± 1.3 ## 
 VenaFlow 5.3 ± 1.3 5.4 ± 1.3 5.2 ± 1.3 # 
 
Table 3: Central hemodynamic results throughout the supine compression protocol. Results are shown (mean ± std) 
for all compression devices at the baseline (1 minute before the start of compressions), the transient state (first 
minute of compressions), and the steady state (last minute of compressions). Significant interaction effects are 
denoted as follows: *Results are different (p<0.05) from baseline; #Results are different (p<0.05) from CGC at the 
corresponding time point; +Results are different (p<0.05) from VenaFlow; ++Results are significantly different 
(p<0.004) from VenaFlow. 
 Baseline First Minute Last Minute 
Heart Rate (bpm)    
 CGC 61.3 ± 9.0 62.5 ± 10.1 62.2 ± 9.8 
 Flowtron 62.5 ± 9.5 61.0 ± 10.0 63.9 ± 10.4 + 
 SCD 62.7 ± 11.5 60.3 ± 10.1 * # 63.3 ± 11.1  
 VenaFlow 62.4 ± 8.5 60.8 ± 9.3 61.3 ± 9.1  
Stroke Volume (mL)    
 CGC 84.5 ± 17.6 85.8 ± 19.0 84.0 ± 19.4 
 Flowtron 83.4 ± 12.7 85.1 ± 13.9 86.1 ± 16.3 
 SCD 84.5 ± 15.4 86.3 ± 15.8 85.3 ± 18.5 




Cardiac Output (L/min)   
 CGC 5.1 ± 1.1 5.3 ± 1.2 5.2 ± 1.2 
 Flowtron 5.2 ± 1.2 5.2 ± 1.2 5.5 ± 1.2 ++ 
 SCD 5.3 ± 1.3 5.1 ± 1.1 5.3 ± 1.3 + 
 VenaFlow 5.0 ± 1.2 5.0 ± 1.1 5.0 ± 1.2  
The CO results for the SCD and Flowtron devices were lower and significantly lower, 
respectively, from the VenaFlow device during the steady state. Otherwise there is a minor 
decrease in HR produced by the SCD during the first minute but the change is not maintained. 
Finally, there is a decrease in the HR in the last minute for the Flowtron. In general, the differences 
between the devices are more significant when seated, thus highlighting the dependence of IPC 
device performance on position [61].   
2.3.2 Arterial Velocity 
The superficial femoral arterial velocity for both the seated and supine protocols is presented 
in Fig. 6. In the supine position (Fig. 6A), increased velocity relative to baseline was maintained 
by the CGC device throughout duration of compressions. The Flowtron exhibited elevated flow 
during steady state. Flowtron and SCD produced lower and significantly lower femoral velocities 
compared with CGC in the first minute of compressions, respectively, whereas the VenaFlow was 
the only device producing statistically lower velocities than CGC in steady state.  
More pronounced effects of CGC were found during the seated protocol (Fig. 6B). In this 
position, CGC was the only device that resulted in significantly elevated arterial velocities from 
baseline for the duration of compressions; the Flowtron showed significantly elevated arterial 
velocities during the first minute only. All commercial devices produced lower arterial velocities 
than CGC throughout compression. Both SCD and VenaFlow were lower than Flowtron as well 




Fig. 6 Arterial beat-by-beat velocity in the superficial femoral artery of the left leg (A – Supine, B – Seated). Results 
are shown (mean ± std) for all compression devices at the baseline (1 minute before the start of compressions), the 
transient state (first minute of compressions), and the steady state (last minute of compressions). Significant 
interaction effects are denoted as follows: *Results are different (p<0.05) from baseline; **Results are significantly 
different (p<0.004) from baseline; #Results are different (p<0.05) from CGC at the corresponding time point; 
##Results are significantly different (p<0.004) from CGC at the corresponding time point; †Results are different 
(p<0.05) from Flowtron at the corresponding time point. 
2.3.3 Venous Velocity 
Average femoral venous velocities over one minute intervals are presented in Fig. 7 for both 
body positions. Within the supine prosition the Flowtron and SCD baseline velocities were 
increased in comparison to the Flowtron baseline velocity; however, as none of these devices 
resulted in siginficant changes from their baseline values in this position it is unlike this initial 
difference affected the statistical results for the comparisons between the devices at later time 
points. In comparison with baseline, the CGC device resulted in significantly increased velocities 
during the first minute of compressions in both body positions; the Flowtron showed an increase 
during the first minute in the seated protocol. Comparing compression devices, CGC showed 
significantly greater velocities than the other devices during the first minute of compression while 
seated, and increased and significantly increased velocity compared to the SCD and VenaFlow, 
respectively, during the first minute while supine. In the last minute of compressions, none of the 
devices showed increased velocity with respect to baseline.  All devices were similar in the last 




Fig. 7 Venous velocity averaged over one-minute time points in the femoral vein of the right leg (A – Supine, B – 
Seated). Results are shown (mean ± std) for all compression devices at the baseline (1 minute before the start of 
compressions), the transient state (first minute of compressions), and the steady state (last minute of compressions). 
Significant interaction effects are denoted as follows: *Results are different (p<0.05) from baseline; **Results are 
significantly different (p<0.004) from baseline; #Results are different (p<0.05) from CGC at the corresponding 
time point; ##Results are significantly different (p<0.004) from CGC at the corresponding time point; +Results are 
different (p<0.05) from VenaFlow at the corresponding time point. 
 The average velocities presented in Fig. 7 include both the periods when compression is 
applied, as well as the time between compressions. Several prior studies, in contrast, have assessed 
IPC performance by considering instead the maximum venous velocity observed during steady 
state compressions only during the time in which compression is applied [9], [15], [24], [37], [57]. 
To facilitate direct comparison with these studies, Fig. 8 presents the average peak velocity of the 
last 3 compressions in each protocol for all devices considered. In the supine position (Fig. 8A), 
all devices except CGC show significantly higher peak velocity compared with baseline and CGC, 
with VenaFlow being significantly higher than all other devices. In the seated posture (Fig. 8B), 
all devices produced significantly elevated peak velocities compared with baseline. As with the 
supine, VenaFlow had significantly higher peak velocity than the other devices, whereas Flowtron 




Fig. 8 Peak venous velocity in the femoral vein of the right leg averaged over 3 cycles within the steady state 
condition (A – Supine, B – Seated). Results are shown (mean ± std) for all compression devices at the steady state 
time point (last 3 compression cycles). Significant interaction effects are denoted as follows: **Results are 
significantly different (p<0.008) from baseline; ##Results are significantly different (p<0.008) from CGC; 
++Results are significantly different (p<0.008) from VenaFlow. 
2.3.4 Venous Displacement 
 In an effort to enable meaningful comparisons between devices with disparate compression 
durations and frequencies, the venous displacements are calculated for one compression period, 
the results of which are presented in Table 4. Also included is an estimate of the venous 
displacement that would be achieved after an hour of steady state compressions. All commercial 
devices had significantly larger displacements per compression than CGC, with Flowtron and SCD 
also displacing the blood further than the VenaFlow in both positions. Over the course of an hour, 
however, CGC in the seated position produces significantly larger displacements than the other 
devices due to the much higher compression frequency. Similarly, the SCD outperforms the 
Flowtron in the seated position, possibly due to the compression frequency. In the supine position, 
Flowtron and SCD outperform the VenaFlow; the SCD also outperforms the CGC. Subject to 
subject variability, as evidenced by the standard deviation of the results, was generally much larger 





Table 4: Venous displacement in the femoral vein throughout the seated and supine protocols. Results are shown 
(mean ± std) for all compression devices at the steady state time point (last 3 compression cycles). Significant 
interaction effects are denoted as follows: ##Results are significantly different (p<0.008) from CGC; +Results are 
different (p<0.05) from VenaFlow; ++Results are significantly different (p<0.008) from VenaFlow; ††Results are 
significantly different (p<0.008) from Flowtron. 
 Supine Seated 
Mean Displacement per compression (cm) 
 CGC 3.4 ± 1.8 2.3 ± 0.8 
 Flowtron 272.2 ± 144.0 ## ++ 95.8 ± 27.5 ## ++ 
 SCD 243.1 ± 131.3 ## + 97.2 ± 27.9 ## ++ 
 VenaFlow 180.3 ± 81.9 ## 75.8 ± 17.5 ## 
Mean Displacement per hr (cm)  
 CGC 13303.5 ± 8637.8  8826.2 ± 2935.2 
 Flowtron 16332.7 ± 8640.1 ++ 5749.9 ± 1651.0 ## + 
 SCD 18289.5 ± 8456.3 ## ++ 7270.5 ± 2037.4 ## ++ †† 
 VenaFlow 10815.1 ± 4911.3  4545.0 ± 1052.1 ##  
    
2.3.5 Muscle Oxygenation 
Tables 5 and 6 present the muscle oxygenation data for the supine and seated protocols, 
respectively. For both positions, all devices induced significantly lower HHb and tHb 
concentrations during steady state operation in comparison with baseline values, thus 
demonstrating the ability of all devices to remove the venous pooling in the lower limbs. Only 
CGC resulted in a sustained effect on the O2Hb concentration as well. Comparing devices, CGC 
was significantly different from the commercial systems in all measures except for O2Hb 
concentration in the supine position for the Flowtron device. We note that the baseline value for 
Flowtron, however, was significantly different from CGC; the change in O2Hb concentration from 
baseline was, in fact, significantly different than CGC during the first minute (p=1.53 x 10-5) and 
last minute (p=1.32 x 10-6), in alignment with all other devices.  
Table 5: Muscle oxygenation values throughout the supine compression protocol. Results are shown (mean ± std) 
for all compression devices at the baseline (1 minute before the start of compressions), the transient state (first 
minute of compressions), and the steady state (last minute of compressions). Significant interaction effects are 
denoted as follows: *Results are different (p<0.05) from baseline; **Results are significantly different (p<0.004) 
from baseline; ##Results are significantly different (p<0.004) from CGC at the corresponding time point; †Results 
are different (p<0.05) from Flowtron at the corresponding time point; ††Results are significantly (p<0.004) 
different from Flowtron at the corresponding time point; &Results are different (p<0.05) from SCD in the 
corresponding protocol. 
 Baseline First Minute Last Minute 
O2Hb (Δμm)    
 CGC 1.0 ± 2.4 -2.4 ± 2.0 ** -1.7 ± 2.3 ** 
 Flowtron -0.5 ± 1.6 ## -1.6 ± 1.9 * -0.8 ± 2.0 
 SCD 0.5 ± 1.4 † -0.2 ± 2.0 ## †† 0.0 ± 2.3 ## 




HHb (Δμm)    
 CGC -2.3 ± 2.5 -5.0 ± 2.6 ** -6.1 ± 2.8 ** 
 Flowtron -1.9 ± 3.1 -3.0 ± 3.2 * ## -4.0 ± 3.6 ** ## 
 SCD -1.8 ± 3.2 -3.2 ± 3.4 ** ## -4.2 ± 3.6 ** ## 
 VenaFlow -1.8 ± 2.7 -2.5 ± 2.6 ## -3.4 ± 3.1 ** ## & 
tHb (Δμm)   
 CGC -1.3 ± 3.9 -7.4 ± 3.2 ** -7.7 ± 3.3 ** 
 Flowtron -2.3 ± 3.7 -4.6 ± 4.1 ** ## -4.8 ± 4.2 ** ## 
 SCD -1.3 ± 4.0 -3.4 ± 4.3 ** ## -4.2 ± 4.5 ** ## 
 VenaFlow -1.0 ± 4.0 † -2.4 ± 3.4 * ##  †† -3.3 ± 4.2 ** ## † 
Table 6: Muscle oxygenation values throughout the seated compression protocol. Results are shown (mean ± std) 
for all compression devices at the baseline (1 minute before the start of compressions), the transient state (first 
minute of compressions), and the steady state (last minute of compressions). Significant interaction effects are 
denoted as follows: *Results are different (p<0.05) from baseline; **Results are significantly different (p<0.004) 
from baseline; ##Results are significantly different (p<0.004) from CGC at the corresponding time point. 
 Baseline First Minute Last Minute 
O2Hb (Δμm)    
 CGC 2.4 ± 2.7 -3.2 ± 4.5 ** -1.7 ± 4.8 ** 
 Flowtron 2.3 ± 2.2 1.0 ± 2.5 ## 0.8 ± 2.6 * ## 
 SCD 1.8 ± 1.9 1.2 ± 1.8 ## 0.7 ± 2.4 ## 
 VenaFlow 2.9 ± 3.5 1.7 ± 3.6 ## 1.0 ± 3.1 * ## 
HHb (Δμm)    
 CGC -2.3 ± 2.6 -6.9 ± 2.1 ** -8.5 ± 2.3 ** 
 Flowtron -1.1 ± 2.8 -2.5 ± 2.8 * ## -4.5 ± 3.2 ** ## 
 SCD -1.3 ± 2.3 -3.4 ± 2.1 ** ## -4.8 ± 2.6 ** ## 
 VenaFlow -1.3 ± 2.5 -2.1 ± 2.1 ## -4.7 ± 2.3 ** ## 
tHb (Δμm)   
 CGC 0.0 ± 4.0 -10.1 ± 5.1 ** -10.2 ± 6.0 ** 
 Flowtron 1.2 ± 2.6 -1.5 ± 2.9 * ## -3.8 ± 3.9 ** ## 
 SCD 0.5 ± 3.0 -2.1 ± 2.6 * ## -4.1 ± 3.5 ** ## 
 VenaFlow 1.6 ± 3.9 -0.5 ± 3.7 ## -3.7 ± 3.7 ** ## 
During the first minute of compression, SCD and the CGC exhibited significantly lower HHb 
concentrations and Flowtron showed modest change. All devices reduced tHb in the first minute 
of compressions with the exception of the VenaFlow while seated. Only CGC significantly 
impacted O2Hb concentration in the first minute of compression. In general, device performance 





2.4.1 Hemodynamic Comparison of the Timing of the Devices  
The CGC system, with its rapid inflation and high frequency, was the only device to produce 
a sustained increase in SV for the duration of the compression in either posture. A similar effect 
was found by Bickel et al. (2011), in which they observed a maintained increase in SV when 
compression was applied twice per minute; however they also saw an increase in the CO [63]. 
Despite elevated SV for CGC, slight reductions in HR result in CO being only slightly elevated 
(p=0.1). Though considerably lower in frequency than CGC, two compressions per minute is still 
generally a higher rate of compression than the three commercial devices tested in this study (SCD 
can have similar compression frequency, depending on venous refill time, see Table 1). As such 
the increased SV could be due to the frequency of compressions and the difference in CO results 
may be due to differences in the subject population (all men vs men and woman in this study), the 
cuff length (foot to thigh vs calf), or the measurement posture (left lateral decubitus position vs 
seated/supine) as the positional differences have been shown to affect results in this study and 
others [61]. Bickel et al. (2011) attributed the increase in CO to the decrease in total peripheral 
resistance (TPR) and an increased venous return [63]. Due to the insignificant change to the CO 
for the CGC the increase is SV is not likely due to a significant change in TPR as the CO and TPR 
are inversely related. Instead the change in SV by the CGC may be due to the compressions causing 
an increase in the arterial-venous pressure gradient; as upon the release of compression, blood flow 
into the limb has been shown briefly elevate due to a transient increase in the arterial-venous 
pressure gradient [25], [27], [64]–[66]. This would result in a higher preload and also explains the 
greater effect in the seated position, as the pressure difference is greater than in supine as the legs 
are further from heart level.  
The increase in arterial-venous pressure, flow enhancement mechanism should be common to 
all devices. However, CGC and Flowtron were the only devices to increase the SV at steady state 
in the seated position. Furthermore, they were the only devices to increase SFA velocity and the 
average femoral venous velocity, with CGC being the only one to sustain the increase on the SFA 
beyond the first minute of compressions. Additionally, the CGC showed significantly greater 
venous velocities than the other devices during the transient state while seated; this result suggests 
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that the CGC device may be more efficient at eliminating the venous pooling that results from the 
seated position. Interestingly, these two devices are on opposite ends of the complexity spectrum, 
as shown in Table 1. The transient effects of the Flowtron are potentially demonstrating the slower 
devices abilities to quickly eliminate the increased venous pooling due to the seated position, the 
slower device may perform better than the VenaFlow as the duration of compression is longer 
causing a greater displacement of venous blood. However, as the effect on the arterial velocity is 
not maintained this could suggest that the CGC’s compressions are more efficient at improving 
peripheral circulation. The frequency of the CGC’s compressions could have a greater effect on 
the arterial-venous pressure gradient as the increase in venous velocity during the transient phase 
is significantly greater than the other devices. The frequency of compression timing could work to 
maintain the lower venous pressure which accounts for the consistently increased inflow of the 
arterial blood to the lower limb. We note that during the first minute of compressions, the SCD 
has already gone through it’s calibration cycle comparing it to other devices at the start of 
compressions is not strictly prudent as it does not have the same venous pooling to act upon. It 
performs no better than any of the commercial devices in the steady state, however, at which point 
ample time had elapsed for all devices to reach the same steady state behaviour. 
 IPC devices with rapid inflation profiles have been shown to produce significantly higher peak 
venous velocities in comparison with slower inflating devices [9], [15], [24], [37], [57]. In 
alignment with these findings, this study finds that the VenaFlow resulted in significant higher 
peak venous velocity compared to the SCD and Flowtron units. The low frequency, rapid inflation 
compression profile of the VenaFlow rapidly ejects the blood from the veins, resulting in high 
peak venous velocities. The CGC device, despite having the most rapid inflation rate of the 
compared devices, had the lowest peak venous velocities of all devices due to the very high 
frequency of compression, which allowed little venous refilling between subsequent actuation 
events. The SCD, which could have higher compression frequencies than the Flowtron and 
Venaflow, had the next lowest peak venous velocity, further suggesting that frequency, and not 
just inflation rate, is an important performance parameter. While the peak venous velocity at steady 
state was elevated from baseline for most cases, the velocity minute averages at steady state 
showed that none of the devices elicited values significantly different from baseline. This suggests 
that potentially the devices are all capable of eliminating venous stasis, but the periods of 
augmented venous flow are confined to the compression periods once at steady state. 
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IPC devices with slower inflation and longer duration compression profiles have been shown 
to result in prolonged increases in velocity during the compression period [9], [10], [37], [57]. As 
such, the average volume of venous blood ejected per compression and over an hour period of 
compressions, has been shown to be higher for slow inflation devices in comparison to rapid 
inflation [9], [37], [57]. In this study, it was found that the slow inflation devices (Flowtron and 
SCD) did outperform the rapid inflation devices (VenaFlow and CGC) in the venous displacement 
per compression. Flowtron and SCD resulted in the greatest (though equivalent) displacement per 
compression likely due to their slower inflation cycles having longer periods of venous velocity 
augmentation. The VenaFlow did result in significantly greater displacement per compression than 
the CGC, again due to the vast disparity in actuation frequency and the resultant impact on venous 
refilling between compressions.  
Though exhibiting the smallest venous displacement per compression, over the course of a 
simulated one-hour compression therapy session, CGC outperformed all other devices in the seated 
protocol and was similar to the other devices for the supine position. This suggests that rapid, high 
frequency inflation, can perform at least as well as the slow, long duration compression protocols; 
assuming that there is not a significantly different impact on diameter by the devices as this metric 
was not measured but could impact the comparative behaviour. The SCD and Flowtron had greater 
displacements per hour than the VenaFlow in both postures, in alignment with the prior 
compression results. Interestingly, despite employing “smart” timing, the SCD did not outperform 
the simpler Flowtron device in any venous blood movement measure (peak velocity, average 
velocity, or blood displacement). These results contrast with Griffin et al. (2007), whose study 
found superior performance of the SCD over a similar Flowtron model [57]. However, this may 
be due in part to differences in cuff length (thigh length cuffs versus calf length in this study), test 
posture (semi-recumbent versus seated/supine), or the subject population (varicose veins versus 
no venous insufficiencies) [57].  
The muscle oxygenation results matched the trends seen in the arterial velocity and SV 
measures. The two “smart” timing devices, CGC and SCD, both resulted in a sustained decrease 
in de-oxygenated hemoglobin throughout the duration of the study. The CGC also resulted in 
significantly lower concentrations of tHb in comparison to the other devices at both the transient 
and steady state in both postures, suggesting that the “smart” timing used by the CGC device is 
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more beneficial and faster to take effect than the devices which use fixed timing. Finally, only the 
CGC resulted in a sustained effect on the oxygenated hemoglobin concentration during the 
transient and steady state conditions in both positions, further indicative of the sustained ability of 
the device to improve the peripheral circulation, as also found with SFA velocity and SV data. 
2.4.2 Quantitative Measures to Determine Performance 
The manufacturers of the majority of commercially available IPC devices relate performance 
of the device to the venous measures collected during the portion of the cycle when the device is 
applying pressure [15]. The means of quantifying the venous return resulting from application of 
the devices vary. It is a matter of some debate whether it is better to have a higher maximum 
venous velocity or a sustained increase in average venous velocity during the compression period 
[6], [10], [15], [24].  
It is possible that the venous measurements are not the best measure of IPC performance. Lurie 
et al. (2008) reported results contrary to the common assumption that the hemodynamic response 
to IPC devices can be attributed solely to the deep veins, instead observing that the superficial 
veins and potential fluid shifts into the intravascular space may play a significant role [67].  
Another possible flaw in the peak venous velocity and venous displacement measures is that they 
do not take into account the velocity of the venous blood during the time in which the cuffs are not 
inflated. Furthermore, the measurements are usually only taken from one vein. As such it is not 
possible to visualize the full picture of what is truly occurring with the venous return. However 
even the minute averages of the venous velocity were not indicative of performance when 
compared to the other physiological measurements.  
The measures of the stroke volume, arterial velocity and muscle oxygenation all showed fairly 
consistent results for the performance of the devices at each time point. Based on the similarities 
in results outside of the venous measurements it may be better in the future to use arterial velocities 
instead of venous to quantify the performance of IPC devices. Additionally, having multiple 
measures to examine the effect of the IPC devices is likely to help quantify the effect of the IPC 




The CGC device outperforms the commercial devices in the seated position, while performing 
at least as well as the other devices in the supine position, for virtually all objective performance 
measures, except for peak venous velocity and venous displacement per compression. The 
VenaFlow outperformed all devices with respect to higher peak venous velocities. The Flowtron 
and SCD had the greatest venous displacements per compression. Both the CGC and the VenaFlow 
are rapid inflation devices with sequentially inflated cuffs. The CGC outperformed the VenaFlow 
in the majority of the hemodynamic responses measures when seated, suggesting that the 
complexity of the “smart” timing likely in combination with the higher frequency of inflation 
resulted in improved performance. While the SCD and Flowtron are both slow inflation devices, 
in this case the “smart” timing used to time the SCD’s compressions did not result in significantly 
improved results when compared to the results of the Flowtron. As such in this case the hypothesis 
that the added complexity of the “smart” timing would result in improved results over a similar 
device was not confirmed. Moreover, the “smart” timing of the CGC showed a more significant 
effect than that used within the SCD when in the seated position. As such the “smart” timing based 
on the cardiac gating proved to be more effective than the “smart” timing based on the vascular 
refill time. 
Going forward it would be valuable to collect several physiological measures to better 
understand the impact of application of the IPC devices. Additionally, while this study determined 
the effect of the IPC devices on a healthy population it would be valuable to have further work 













Wearable sensors for physiological monitoring are becoming ever more prominent as medical 
and consumer products, enabling medical professionals and general consumers to track vitals 
continuously during activities of daily living. For clinical applications, they are being adopted to 
enable untethered monitoring of patients in the hospital and home care settings, thus affording a 
more complete record of a patient’s health than can be obtained during a standard visit [68]–[71]. 
For both commercial and professional adoption, wearable sensors must be reliable, non-invasive, 
compact, and power efficient [41], [48], [68]–[71].  
One of the most prevalent wearable sensor technologies is for heart rate monitoring, which is 
found in virtually all fitness monitors, due in part to the correlation between heart rate and physical 
exertion [20], [72]. Wearable heart rate monitors generally come in two classes: electrical pulse 
detection, similar to a traditional electrocardiogram (ECG); and photoplethysmography (PPG), an 
optical technology found in modern fitness and “smart” watches, as well as peripheral pulse 
detection sensors in clinical settings. PPG sensors are more convenient for integration into day-to-
day life due to their small profile and cost in comparison to ECG based devices [47], [48]. PPG 
relies on a light source and photodetector pairing in order to illuminate the biological tissue and 
measure the variation in light intensity that results from the interaction between the light 
propagation and changes in blood volume under the probe [41]. Specifically, the AC component 
of the waveform contains information regarding the arterial blood volume changes in the area 
under the sensor, which corresponds to the person’s cardiac cycle. The pulse rate is derived from 
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the peaks of the PPG waveform and has been shown to correspond to the R-R interval of an ECG 
waveform, demonstrating that this method can accurately measure heart rate [41]–[43].  
PPG sensors typically have one of two configurations; transmittance- or reflectance-based 
sensors [41], [47], [73]. For transmittance-based sensors, the biological tissue is placed between 
the emitter and detector components, and thus the detector collects light that has passed completely 
through the tissue sample. This method is employed in thinner segments of the body, such as the 
fingers, ears, or toes [41], [47], [73], [74]. Reflectance-based sensors orient the emitter and detector 
components in approximately the same plane, which is then placed on the tissue of interest; the 
detector then collects light reflected back from the tissue sample. Because of the configuration, 
reflectance-based sensors can be used at more diverse measurement sites than transmission-based 
sensors. In clinical environments, transmittance-based sensors are typically employed due to their 
high accuracy; however, reflectance-based sensors are preferred for wearable sensor designs due 
to their versatility [75].  
The skin tone of the user can affect performance of reflectance-based sensors [46], [76] by 
modulating the signal amplitude with minimal impact on the signal shape; therefore, it has been 
suggested that a higher intensity of light is required for darker skin tones in order to achieve the 
same signal strength and signal to noise ratio (SNR) with respect to physiological noise [46]. This 
suggests that the light intensity could be calibrated to achieve the optimal signal strength for a 
specific user and sensor location on the body [44], [74], [77]. However, calibration of PPG devices 
has primarily been done on light-skinned individuals, which results in poor performance on darker 
skin tones [50], [51]. Thus, a device’s performance should be assessed on a wide range of skin 
tones to ensure that the quality of the pulse signal is adequate for all skin pigmentations. A pulse 
sensor with the capability to adjust the intensity of the light to maintain the signal integrity 
regardless of skin pigmentation would be beneficial for achieving the best sensor performance for 
a diverse population. 
Optical pulse detection at peripheral locations, such as the upper and lower limb, has been 
demonstrated, particularly in non-motion conditions [44]–[46], [49]. Studies exploring lower limb 
detection have been limited to a single measurement site with no examination of optimized site 
selection based on signal strength or susceptibility to motion interference. Given differences in 
local vasculature and perfusion, it is expected that signal quality (strength and reflectance) will 
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vary with the selected measurement site [46], [49], [78]. It has been shown that different locations 
on the same subject’s arm resulted in signals with different amplitudes [49], [78]. In addition, when 
testing with multi-channel PPG sensors, the configuration of the sensor’s photodiode and red and 
infrared (IR) paired LEDs can affect the signal measured from the same location during movement 
[69], [79]. It remains to be investigated whether the signal acquisition could be improved during 
non-motion and motion conditions utilizing multiple LEDs and LED illumination configurations 
rather than the standard two LEDs fixed in position and paired to a photodiode.  
A key performance metric for a wearable technology is battery life, as the device should be 
able to function continuously throughout the day. The LEDs used in wearables are one of the larger 
power drawing elements of the design [73]. There have been efforts attempting to develop low-
power devices [70], [73]. Mendelson et al. (2006) noted that reducing the current drive to the LEDs 
would increase the battery life but sacrifice signal quality [73]. An increase in the number of 
detectors was proposed in order to mitigate the signal loss by capturing more back scattered light 
[73]. As an alternative, determination of the LED configuration resulting in a measurable PPG 
waveform at the lowest current requirement could improve sensor efficiency. 
The objective of this manuscript is to develop a multi-LED PPG sensor and calibration scheme 
to extend battery life of a wearable heart rate monitor that is robust to location and skin 
pigmentation. In investigating application location, we consider the positional sensitivity to 
different types of movement to better facilitate the wearable nature of the sensor. Specific 
objectives to be addressed are: (i) test whether the calibration cycle can find the LED configuration 
for each individual that results in the highest pulse signal amplitude; (ii) determine if there is a 
location on the lower limb that allows for the LEDs to be at a lower intensity setting while still 
resulting in a reliable signal; and (iii) test the effect of movement of the lower limb on the signal 
captured by the sensor and if there exists a location on the lower limb where the pulse rate 
measurement is less susceptible to movement. These contributions can result in improved pulse 
sensor technology while providing information on the location on the lower limb that should be 
used for pulse rate measurements both at rest and during movement. 
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3.2 Sensor design 
3.2.1 Sensor Layout 
The customized sensor head, shown in Fig. 9, consists of 6 symmetrically spaced green LEDs 
(AA3528CGSK Kingbright, 574 nm peak wavelength, half-intensity angle ± 60˚) arranged in a 
ring. The peak wavelength of the LEDs falls within the range of wavelengths that has been shown 
to result in better detection of pulsatile blood volume changes across several skin tones (510 to 
590 nm) within the range of visible and IR light (400 to 1000 nm) [46]. In addition, this wavelength 
was chosen as it has a shallower penetration depth into the tissue than red and IR light [46], [49], 
[76], [80], which results in the sensor’s performance being less effected by the anatomical 
measurement site, as the underlying tissues and vessels attribute less noise in the reflected light 
[46], [49], [76], [80]. Cui et al. (1990) demonstrated that, in locations where there is a lower 
concentration of blood vessels, green light outperformed red light in returning a pulsatile signal 
[46]. Furthermore, it has been shown that reflectance pulse sensors that use green light are less 
sensitive to movement than red [81] and IR [49] based sensors. 
 
Fig. 9 Schematic of the sensor head. The sensor is 18 mm 
(vertical direction) by 18.5 mm (horizontal direction) with a 
thickness of 3.5 mm. 
At the center of the LED ring is a single photodiode (PD) (APDS-9008 Avago Technologies, 
peak sensitivity wavelength 565 nm); the distance from the center of the PD to the center of each 
LED is 5 mm. The LEDs are symmetrically spaced around the PD at the chosen distance to 
maintain the AC component of the PPG waveform without the need for higher intensities; as it has 










and detector is increased the signal amplitude of the detector will decrease exponentially [45]. The 
selected LED configuration also ensures that the proximity of the sources and detector does not 
result in the saturation of the photodiode with the DC component of the PPG waveform that results 
from the scattering of the emitted light in the upper blood-free layers of the skin [45]. Previous 
sensor studies have implemented a similar ring configuration, though the LEDs and PD positions 
were switched; that is, they comprised a ring of PDs surrounding two pairs of red and IR LEDs 
[79]. 
Each LED on the sensor head was assigned to a separate channel of a digital potentiometer 
(AD2506 Analog Devices, terminal resistance: 10kΩ) to enable independent control of the supply 
current, thus maximizing tunability. A DC current was supplied to the LEDs so that the luminous 
intensity emitted could be quantify based on the LED characteristics [82]. The LEDs chosen for 
this design have a linearly increasing relationship between the current drawn and the luminous 
intensity [82]. As such, a lower LED intensity should result in a longer battery life for the wearable 
sensor. The PD circuit isolates the frequencies of interest within the pulsatile signal using a 
combination of high and low pass filters with cut-off frequencies of 0.59 Hz and 3.32 Hz, 
respectively, which spans the frequency range of interest; this range corresponds to pulse rates 
between 35-199 bpm. The circuit removes the DC component of the pulse signal that is generated 
by the non-pulsatile surrounding tissue, venous blood, skin, and bone [41], [77], [83], and adds a 
reference voltage of 2.5V. A gain stage further increases the amplitude of the pulse signal. The PD 
chip itself contains a current to voltage converter, and thus additional external circuitry for this 
function was not required [84]. 
3.2.2 Calibration Cycle 
The calibration cycle was developed such that, all permutations of the LEDs, from a single 
LED to all six illuminated simultaneously, are tested at three different intensity levels, leading to 
a total of 189 combinations. For each of the three intensity settings, the cumulative intensity of the 
illuminated LEDs was normalized to the number of LEDs lit in each permutation. That is, for a 
given intensity setting, the illumination intensity was the same, regardless of the number of 
illuminated LEDs. This enabled direct comparison of performance across all 63 LED illumination 
combinations. During testing, each LED combination was maintained for fourteen seconds; a 
seven second buffer was used to allow the signal time to settle after the change in configuration, 
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while the last seven seconds were used for data analysis. Each sensor head had a total calibration 
cycle time of 44.1 minutes for all three intensity levels and configuration permutations. 
Each of the three sensors used in the study was consistently used in the same orientation and 
the same measurement location. As such should a trend appear in the pulse data collected which 
certain configurations it may be a result of the LEDs being brighter. However, while it could be 
intrinsic LED differences, preliminary testing was done to characterize the sensors’ performance 
when removed from ambient light. The testing resulted in the average standard deviation around 
the average photodiode response to be within +/- 1.0% for each LED configuration across the three 
sensors when set to the lowest intensity used during the calibration cycle. 
3.3 Experimental Methods 
3.3.1 Protocols 
The study was divided into three separate protocols. In all protocols, the participants were 
seated with their backs upright, knees at a 90˚ angle, and their lower legs perpendicular to the 
ground. The pulse signal was collected from three locations on the lower limb; the shin, the ankle, 
and the top of the foot, see Fig. 10. All participants were asked to remain still and refrain from 
speaking to reduce data contamination from noise and extraneous motion for the duration of the 
data collection. 
The first protocol was designed to determine the lowest light intensity necessary for a 
measurable PPG waveform for two participants at the extremes of the considered skin 
pigmentation levels at each of the three lower limb measurement locations. The protocol was 
intended to aid in the identification of three target intensity levels (i.e. low, medium, and high) per 
measurement location, with the expectation that the low and high levels were representative of the 
intensity levels acceptable for the light and dark pigmentations, respectively. The medium light 
intensity level is the midpoint between the low and high setting. The three intensity levels 
determined within this pilot protocol were used in the subsequent calibration protocol. Two LEDs 
directly across from each other (LEDs 2 and 5, see Fig. 9) were illuminated on the sensor head and 
placed against the skin in each of the three measurement locations. This configuration was 
employed as it mimics the configurations employed in several commercial wearables, such as the 
Fitbit [85]. The intensities of the LEDs were systematically increased by stepping down the 
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resistance of the digital potentiometer by step sizes of 39 Ω while simultaneously recording the 
light returned to the PD. Each LED and intensity configuration was maintained for 11 seconds; a 
4.5 second buffer was used to allow the signal to settle after the change in illumination intensity, 
while the last 6.5 seconds were used for data analysis. A smaller buffer was used for the pilot 
testing in comparison to the buffer size for the calibration cycle because pilot testing indicated that 
the resulting PPG signal was less impacted by the illumination intensity change of one step size in 
comparison to the modification of the LED configuration or larger illumination intensity changes, 
and thus required less settling time. 
The second protocol used the calibration cycle in order to test if there exists an ideal LED 
illumination combination for maximizing the signal amplitude at the lowest intensity possible for 
a given user and measurement location. In the second protocol, the full calibration cycle was run 
on all participants with the intensities determined from the first protocol. The third protocol was 
designed to test the sensitivity of the sensor to motion at each measurement location. For this 
protocol, all six LEDs were illuminated at their highest intensity setting per location. Participants 
were asked to complete five different types of controlled movements, the order of which was 
randomized for each participant. Each of the five movements was performed at a frequency of 40 
bpm (0.67 Hz) as indicated by a metronome. The five types of movement were: (1) ankle pivots 
(pivoting their foot at the ankle in the medial and lateral directions with the heel on the ground); 
(2) calf raises (keeping ball of the foot on the ground and lifting their heel); (3) foot flexes (lifting 
their foot upwards bending at the ankle while keeping their heel on the ground); (4) foot lifts 
(keeping their foot parallel to the ground and lifting their leg); (5) toe flexes (lifting their toes 
upward with their feet still resting on the floor). 
The experimental protocol for this study received clearance from the University of Waterloo 
Research Ethics Committee (ORE #22756) and conformed to the Declaration of Helsinki. 
3.3.2 Participants 
Two healthy participants participated in the pilot intensity protocol, which were representative 
of the participants with the lightest and darkest skin pigmentation of all subsequent protocol 
participants. RGB values were measured on the lower leg for each participant to quantify 
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pigmentation levels; the lighter skin tone was measured as 200 172 153 and the darker skin tone 
was measured as 143 112 84. 
Ten healthy participants (26.5 +/- 5.3 years old) were recruited for the calibration protocol. The 
average height and weight of the participants were 170.0 cm +/- 9.6 cm and 75.3 +/- 20.7 kg, 
respectively. The calibration protocol participants had varying skin pigmentations and self-
identified their race, listed here in ascending order from lightest to darkest skin pigmentation: 4 
Caucasians, 1 Asian, 3 South-East Asians, 1 South Asian, and 1 African-American. 
For the motion protocol, ten healthy participants (26.5 +/- 5.3 years old) participated in the 
study with average height and weight of 171.0 cm +/- 10.1 cm and 76.8 +/- 22.2 kg, respectively. 
In ascending order from lightest to darkest skin pigmentation, participants were self-identified as: 
5 Caucasians, 1 Asian, 2 South-East Asians, 1 South Asian, and 1 African-American.  
3.3.3 Measurements 
Three reflectance pulse sensors were used to simultaneously record the peripheral pulse rate 
from the shin, the ankle, and the top of the foot to enable monitoring of the circulation in the lower 
limb, see Fig. 10. These locations were chosen based on expected differences in the underlying 
physiology that will impact sensor pulse detection and movement artifacts in the signal waveform 
influenced by the range of motion at each location and relative distances to the leg joints. The 
sensor order was held consistent across participants; that is, the same sensor was always used for 




Fig. 10 The measurement locations on the left leg used in the study and coordinate system definition. 
Anatomical landmarks and dimensions were used to place the sensors in a similar region across 
all participant’s legs. The left leg was chosen as the measurement limb and was consistent across 
all participants. For the shin (L1) and ankle (L2), the sensors were taped in place such that LED 6 
was at the highest superior position (y-direction, see Fig. 10). For the foot (L3), the sensor was 
taped in place such that LED 6 was the most medial (highest z value).  
The three reflectance pulse sensors measured the pulse rate and a three-lead chest 
electrocardiogram (ECG) (Pilot 9200, Colin Medical Instruments Corp, San Antonio, Texas, USA) 
measured the heart rate. All measurements were concurrently acquired at 1 kHz using a Powerlab 
data acquisition system (Powerlab, ADInstruments, Colorado Springs, Colorado, USA) for 
comparison during each study protocol. For the intensity pilot protocol, a MM400 digital 
multimeter (MM400, Klein Tools, Inc., Lincolnshire, Illinois, USA) was used to measure the 
current supplied to each of the LEDs at each intensity setting tested. This current was converted to 
luminous intensity using the relationship provided on the datasheet for the LEDs. 
3.3.4 Data Analysis 
Data collected were filtered using a digital low pass filter to remove high frequency noise 










the lowest intensity that resulted in the same amplitude of the pulse signal for each participant 
(skin tone) and location without performance errors. The amplitude (A) of each illumination 
configuration was considered as the average difference between the global maximum peak voltage 
(PVmax) and the global minimum peak voltage (PVmin) within the pulse signal per heartbeat, 
𝐴 =
∑ PVmax −  ∑ PVmin
ℎpulse
    [V]   (1) 
where hpulse is number of detected heartbeats in the analyzed PPG signal, see Fig. 11. The tolerance 
for equivalent amplitudes between the two participants was ± 0.004 V. 
 
Fig. 11 Amplitude components of the PPG waveform for one heartbeat. 
For a given illumination configuration, the performance error (PE) is defined as the difference 
between the number of heartbeats determined from the R peaks of the ECG waveform (ℎecg) and 
ℎpulse, 
PE = |ℎecg − ℎpulse|          (2) 
The Matlab R2017b function findpeaks was used in order to capture the peaks of the ECG and 
PPG waveforms. The performance of the software was visually confirmed to be accurate by an 
observer for each measurement location per individual for all cases.  
As discussed in Section 3.2.2, the illumination intensity was normalized such that it was 
nominally the same regardless of the number of LEDs in use for a given setting, low, medium, or 
high. The individual drive current for each LED within a specific LED configuration was identified 






protocol. The tuned setting for each LED per target cumulative light intensity level was confirmed 
via repeated measures of the total light intensity at each LED configuration. 
For the calibration protocol, the goal was to identify the LED illumination combination that 
resulted in the best signal, defined as the highest signal amplitude PPG waveform at the lowest 
intensity setting that did not incur performance errors, for each location and participant. The 
configurations that resulted in performance errors (Equation 2) were excluded from consideration 
when determining which signal had the highest amplitude (Equation 1). 
Five different movements were tested with the sensors in place for the motion protocol. Motion 
artifact and the signal-to-noise ratios were used to quantify the sensor’s pulse signal strength in 
comparison to that of the noise generated from the movements. The motion artifact ratio (AR) was 
taken as the average signal amplitude over 30s of movement (𝐴mov) divided by the average signal 
amplitude over 10s of rest data (𝐴rest) directly prior to movement [47], [49],  
AR =  
𝐴mov
𝐴rest 
        (3) 
The SNR was computed as the ratio between the maximum power within the pulse rate frequencies 
(𝑃pr) and the maximum power of the movement frequencies (𝑃noise) from the Fourier transformed 
signal, computed as  
SNR =  10Log10 (
max (𝑃pr )
max (𝑃noise )
) [dB]         (4) 
The range of frequencies of the movement was taken as the set movement frequency +/- 5% 
tolerance (0.63 - 0.7 Hz). The range of frequencies of the pulse rate was determined based on the 
ECG trace during movement, which was unaffected by the lower limb motion. 
3.3.5 Statistical Analysis 
Mixed effects models were employed to statistically compare the results from the motion 
protocol.  The model considered each movement type and modelled the resulting motion artifact 
and the SNR based on the measurement locations as factors. These models contained three paired 
comparisons within the location factor. Hypothesis tests were performed using two-sided t-tests. 
Initially, the level of significance was set as p<0.05. However, in order to avoid Type I errors due 
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to multiple comparisons, the Bonferroni method was used to adjust the level of significance [62], 
which reduced it to p<0.02. 
3.4 Results and Discussion 
3.4.1 Intensity Setting with Varying Skin Tones  
It has previously been shown that for a fixed green emission wavelength, the signal for a 
reflectance-based PPG was higher for light skin tones compared to darker skin tones [46], [76]. A 
similar skin tone-reflectance signal relationship was observed in this pilot, in which the intensity 
of the LEDs was consistently lower for the participant with a light skin tone for the same signal 
amplitude of both participants. The intensity settings of the light skin participant were used as the 
low intensity settings for the subsequent calibration protocol, while the intensity settings of the 
participant with the darker skin tone were used as the high intensity settings; this ensured that the 
calibration protocol would function for all explored skin tones. The medium intensity setting was 
chosen to be half-way between the low and high intensities. Table 7 shows the intensity values 
obtained in this study. Note that the medium intensity is not exactly halfway between low and 
high, but rather is the intensity setting that fell closest to this value; as the intensity values were 
constrained by the step size of the digital potentiometer. 
Each location required different intensity settings to result in the same amplitude of the pulse 
signal. This is consistent with signal amplitude differences across different measurement locations 
reported in prior research [49], [74], [78]. Both participants required the lowest luminous intensity 
at the foot measurement location. It is hypothesized that this is because the foot is more 
vascularized than the ankle or calf. This hypothesis is supported by the evidence that reflected PPG 
signals are typically greater in quality and magnitude when measured from areas of higher 
Table 7: Calibration intensities resulting in the same amplitude across 
location and skin tone. 
Measurement 
Location 
Luminous Intensity Settings (mean +/- st. dev) 
[mcd] 
Low Medium High 
Foot 7.7 ± 0.1 14.4 ± 0.1 21.7 ± 0.3 
Ankle 9.8 ± 0.1 68.1 ± 2.3 122.5 ± 5.0 





vascularized areas with greater capillary densities [44]. The greater capillary density has been 
modelled to help the PPG amplitude as the transmural pressure from the arteries causes pulsatile 
modulations in the capillary beds thereby contributing to the PPG waveform [83]. Furthermore, it 
has been proven that most synovial joints have a high density capillary very superficially located 
[86]; and the foot measurement location is the only location located over planar synovial joints, as 
the shin site is located over the tibia and the ankle site is located over the calcaneus.  
The participant with the dark skin pigmentation required a larger variation of intensities 
between locations than the participant with the light skin pigmentation. The differences in intensity 
for the participant with darker skin pigmentation could be attributed to different concentrations of 
melanin at the different sensor locations. Melanin effects the pigmentation of the skin, and has 
been proven to absorb large amounts of light emitted at shorter wavelengths [76]. The RGB values 
were only recorded at the shin as such difference concentrations could be present to impact the 
intensity required at each location. Another contributing factor could be the temperature of the 
skin and the effect on peripheral circulation. Cold temperatures have been shown to reduce the 
amplitude of PPG waveforms [80]. Attempts were made to control the room temperature where 
the testing occurred, however, skin temperature at the measurement location was not recorded. 
Therefore, it is possible the participant with dark skin pigmentation experienced vasoconstriction 
due to the localized temperature. 
3.4.2 Calibration Cycle 
An example of the pulse signals measured from each location at the high intensity, as well as 
the reference ECG trace is presented in Fig. 12. A DC offset and additional gain has been added 
to the pulse signals for plotting purposes. The R peak of the ECG and the peak of the PPG 
waveform denote the start of the systolic phase of the cardiac cycle [43]. Furthermore, the phase 
delay from the R peak of the ECG to the peak of the PPG waveform is the pulse wave transit time 
to the lower limb. The minor phase delay between the peripheral sensors measures the pulse transit 
time from the shin to the ankle and then to the foot. The three PPG signals are generally similar, 




Fig. 12 Example PPG signals and corresponding ECG trace for one participant with additional gain and DC offsets. 
Depending on the measurement site, different LED configurations were found to provide the 
best PPG signal, as defined in Section 3.3.4. For eight of the ten participants there was a 
configuration that resulted in a pulse signal that had no performance errors at the lowest of the 
three intensity settings, though the configuration generally differed somewhat between 
participants. The amplitude of two of the participants’ foot signals steadily decayed over time. 
This is possibly due to a physiological response to remaining still for the length of the calibration 
cycle, resulting in perfusion changes in the lower limb. These two participants’ foot signals were 
excluded from the summary of the results in Table 8, which indicates the LEDs illuminated (refer 
to Fig. 9 for the numbering convention) and minimum illumination setting that resulted in no 
performance errors; the participants are listed in order of ascending skin pigmentation.   
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The calibration cycle resulted in several trends with respect to the optimal LED configuration. 
The calibration cycle enabled the sensor to have the flexibility to find the illumination settings that 
worked best based on the underlying physiology; while the exact configurations vary, there was a 
visible trend toward illuminating LEDs from one side of the sensor resulting in the best signals at 
the shin and the foot locations. The side of the sensor that shows this trend was different in each 
of the locations, which suggests the performance difference may be due to the positioning and 
concentration of the blood vessels in those anatomical locations. Similarly, Lee et al. (2016) tested 
21 locations in close proximity on the wrist and discovered significant differences in their 
measurements based on the capillaries and blood vessels under the measurement locations [78].  
It is possible that the trends favouring one side of the sensor seen in Table 8 may be a result of 
the LEDs being brighter. Alternatively, it is hypothesized the tissue underneath the sensor 
encompasses the change in amplitude between the two sides of the sensor. As seen in the 
preliminary testing results discussed in Section 3.2.2, the photodiode response was similar across 
all configurations. Further preliminary testing was done to test all three sensors at the same 
measurement location on the shin to test if the best configuration that resulted followed the same 
trend of favouring one side seen in Table 8. While the configuration that produced the best signal 
Table 8: LED combination resulting in the best signal. Participants are listed in ascending order of skin 
pigmentation (i.e. participant 1 has the lightest pigmentation; participant 10 has the darkest). 
Participant 













1 3,4,5 Low 3,4 Low 1,3,4 Low 
2 5 Low 1,6 Low 1,2 Low 
3 1,6 Low 2 Low 3 Low 
4 1,2 Low 3 Low --- --- 
5 6 Low 3 Low 1,2,5 Low 
6 5 Low 1,2 Low 1 Low 
7 5 Low 5 Low --- --- 
8 1 Low 5 Medium 1 Medium 
9 1 Low 2 Low 3 Low 
10 6 Low 1,5 Medium 1 Low 
 





varied amongst the sensors, the trend continued of the best configuration including the LEDs from 
the upper half of the sensor (LEDs 1, 5 and 6, see Fig. 9) for all three sensors. The differences in 
the best configuration could be attributed to minor variation in the placement of the sensors as well 
as the contacting force used to secure the sensor in place, as the contacting force has been shown 
to have a significant impact on the PPG signal [87]. This lends credence to the hypothesis that the 
trend of one side of the sensor working better at the shin and foot is due to the underlying 
physiology rather than sensor bias. For the sensor on the foot it appears that more closely packed 
lateral and intermediate cuneiform bones is beneficial in comparison with the metatarsals for PPG 
measurement. Similarly, the sensor on the shin appears to be negatively affected by the tapering 
of the tibialis anterior muscle over the tibia in the sensor location.  
 Table 8 suggests that configurations with fewer LEDs illuminated tend to produce the best 
results. As discussed in Section 3.2.2, the illumination intensity was normalized such that it was 
nominally the same regardless of the number of LEDs in use for a given setting, low, medium, or 
high. As such, with more LEDs in use, the light was more diffuse, whereas fewer LEDs led to 
more intense localized light. Therefore it is hypothesized that having fewer LEDs illuminated at 
higher intensities in a localized region resulted in greater reflectance from the underlying 
vasculature when compared to the more diffuse illumination of many LEDs. More specifically, 
diffuse illumination led to an increased DC component of the signal, which obscured the pulsatile 
portion of the signal. The Beer-Lambert law states that the intensity of the light decreases 
exponentially as the penetration depth increases when in an absorbing medium [68]. We postulate 
that more diffuse light conditions resulted in a similar effect to lower intensity conditions, causing 
the emitted light to scatter on the bloodless shallower levels of the skin. It has been shown that 
higher intensities of light result in higher amplitudes of the PPG waveform [77]; however, this 
result shows that the intensity of the light is more effective in improving the amplitude if applied 
in higher concentrations. 
The amplitude of the pulse signal averaged across all configurations with the same number of 
LEDs lit for one participant is presented in Fig. 13. The averaged data elucidate the trend in the 
PPG signal amplitude as increasing numbers of LEDs are lit. The maximum and minimum 
amplitude based on the number of LEDs lit are also presented to show the range of potential values 
for the one participant. The calibration cycle at the highest intensity is displayed, as this intensity 
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results in all configurations being free of performance errors for the selected participant. One 
participant was used as not all participants had calibration cycles free of performance errors. 
Further, the trends exhibited for the sample participant were similar across the other participants.  
The maximum amplitude was observed to generally decrease when greater than 1 LEDs were 
illuminated for all measurement location, with the exception of the ankle, which was relatively 
insensitive to the illumination condition. Fig. 13 also highlights the wide range of measured 
amplitudes for configurations with the same number of illuminated LEDs. Furthermore, at the shin 
and ankle locations, the average signal amplitude does not change significantly as the illuminated 
LEDs increases, however large changes are observed in the maximum amplitude. These results 
demonstrate the importance of the calibration cycle to find the configuration that results in the 
maximal amplitude, which can be significantly higher than another configuration with the same 
number of LEDs illuminated. These findings further support the benefit of multiple LEDs and 
independent control capability to maximize the signal captured by the sensor. 
 
 
Fig. 13 Average, maximum, and minimum pulse signal amplitudes for the 6th participant based on the 
number of LEDs lit for each measurement location. 
A measurable PPG signal was acquired for 8 of the 10 participants at the lowest intensity setting 
for all measurement locations, whereas the remainder of the participants (2 out of 10) required the 
medium intensity setting in at least one location. The participants requiring the medium intensity 
setting had darker skin tones, further supporting the need to calibrate sensor performance across a 
spectrum of skin tones due to performance differences [46], [50], [51], [76]. The adjustable 
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intensity settings allowed the sensor to adapt to different skin tones and to conserve battery life by 
increasing the intensity only to levels required for the best signal acquisition.  
All of the configurations that required the medium setting were on the ankle or foot. However, 
while the shin does not require the medium settings, its low intensity setting does have the same 
power requirements as the foot’s medium setting, as seen in Table 7. As such it holds no benefit 
to go with the shin over the foot with respect to power consumption. However, both the shin and 
the foot would be beneficial in comparison to the ankle in terms of allowing the use of intensity 
configurations with less power consumption. 
3.4.3 Movement Effects 
The motion protocol compared the sensor response at all locations to each of the five 
movements described in Section 3.3.1. The motion response was quantified by the motion artifact 
(Equation 3) and the signal to noise ratio (Equation 4). Within the results of the motion artifact it 
is preferable to have a lower motion artifact, as this indicates that the amplitude during movement 
is not altered from that during the rest condition. However, with the results of the signal to noise 
ratio, it is preferable to have a higher result as this indicates that the heart rate frequency contained 
by the pulse signal has not been obscured by the frequency of movement. The results of the motion 
protocol are presented in Fig. 14. 
 
Fig. 14 Average movement response of the sensor at each location for all movement types (A – Motion 
artifact; B – Signal to noise ratio). 
Within the ankle pivoting and the foot flex movements, the shin had a statistically (p<0.02) 




is unsurprising given the relatively mild shin movement in this region for such motions. The calf 
raise resulted in the shin having a statistically (p<0.02) lower motion artifact than the foot, 
similarly within the toe flex movement, the ankle and shin had statistically (p<0.02) lower motion 
artifacts than the foot, which is expected as the extensor digitorum longus muscle involved in these 
movements runs underneath the sensor location on the foot. The ankle pivoting movement resulted 
in the foot having statistically (p<0.02) lower motion artifacts than the ankle, which is somewhat 
surprising, given the greater acceleration experienced at the foot location for this motion however 
is likely due to the measurement location of the ankle as the location does constrict and stretch 
with the pivoting movement. The variance in the results suggest that the ankle and foot signals’ 
resistance to motion are dependant on the type of movement.  
Within each of the five types of movement tested, the shin had the lowest motion artifact 
overall. The SNR for the shin was also on average higher than the response of the other locations. 
This implies that the shin measurement location is more resistant to movement than the ankle or 
foot. Furthermore, this suggests that while the movement does affect the amplitude of the signal, 
the pulse frequency is not completely obscured during the movement when measuring from the 
shin. The shin having a lower motion artifact can be attributed to this location being furthest and 
therefore less affected by the majority of the joints and muscles manipulating the movements in 
the cases tested. Additionally, it has been shown that measurement locations on the peripheral sites 
of the arms, fingers and palms, have greater motion artifacts than those further from the periphery, 
this was attributed to the increased vasculature in the periphery resulting in greater blood volume 
changes during movement [49]. Based on the results of the study the increased motion artifacts 
found in the ankle and foot may be due to a higher number of vessels in the measurement location 
coupled with the increased proximity to the origins of several of the movements in comparison to 
the shin. 
3.4.4 Limitations 
The order in which the configurations were tested was consistent across all participants. Based 
on the duration of the calibration cycle it is possible that minor perfusion changes occurred that 
may have impacted which configuration was deemed best. Furthermore, the skin temperature at 
the sensor locations was not recorded so as to determine if the skin temperature played a role, 
through vasoconstriction with cold or vasodilation with heat, in determining the configuration with 
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the strongest amplitude. Finally, the sensors were only tested on the left leg of all participants and 
whether limb dominance would affect the results of the calibration cycle was not tested. 
3.5 Conclusions 
This study showed that the calibration cycle could be used to identify the LED configuration 
that maximized the pulse amplitude for each individual and measurement location at the lowest 
LED intensity setting without compromising sensor performance. As such the calibration cycle 
could potentially improve the battery life for each individual and measurement location without 
compromising the performance across different skin tones. Overall, the light intensities required 
to acquire the PPG waveform at the foot and the shin measurement locations resulted in the lowest 
power draw. However, the shin location was the most resistant to movement of the three locations. 
The motion conditions tested resulted in artifacts that overpowered the physiological signal for a 
subset of the test. However, the PPG waveform was still visible for several trials suggesting the 
potential to capture the pulse signal during certain motion conditions. 
Multi-channel sensors with the ability to switch between individual PD channels have been 
shown to have certain channels be more resistant to motion artifacts in the pulse signal [69], [79]. 
As such future work should be done to test the calibration cycle during movement to see if there 
is a LED configuration that is more resistant to movement. Positional changes will result in 
perfusion changes in the sensor sites, the calibration cycle should therefore be tested in multiple 
positions to see if the ideal configuration shifts with posture. Additional testing should be done to 
determine if the calibration cycle will need to adjust the best configuration periodically as the 
sensor is worn over an extended period of time. As the shin location was the most resistant to 
movement, further testing could be done on the upper portion of the leg to see if the trend of 










4.1 General Discussion 
This thesis included two studies; one study examined the efficacy of the “smart” timing of a 
new IPC device built in-house in comparison to other commercial IPC devices with both fixed and 
“smart” timing of the compressions; the second study focused on the development and testing of 
a pulse sensor that could be integrated into the new IPC device to further improve its “smart” 
timing.  
4.2 Summary of Findings 
The first study compared the custom CGC device to other commercial devices to determine if 
one form of “smart” timing was more effective and if the devices which used “smart” timing 
resulted in significantly greater hemodynamic responses in comparison to the devices which used 
fixed timing. The custom IPC device used “smart” timing to apply compressions only during the 
diastolic phase of the cardiac cycle. This IPC device was compared to a device which used a similar 
rapid inflation, short duration profile but with fixed timing (VenaFlow), a device with a slow 
inflation, long duration compression profile (Flowtron), and a device which used a different form 
of “smart” timing to time compressions to the vascular refill time of the individual (SCD).  
While seated, the CGC device resulted in significantly elevated muscle oxygenation, stroke 
volume, arterial velocity, and estimated venous blood displacement per hour in comparison to the 
commercial devices. This suggests that the CGC device was more efficient in returning venous 
blood to the heart and improving peripheral circulation. The added complexity of the “smart” 
timing for the CGC device was justified as it resulted in improved performance over a similar 
device which used fixed timing. However, the added complexity of the “smart” timing of the SCD 
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did not result in significantly different hemodynamic responses in comparison to the Flowtron 
which used fixed timing. Additionally, the “smart” timing used by the CGC device to compress 
rapidly during the diastolic phase of the cardiac cycle resulted in improved performance in 
comparison to the SCD which used “smart” timing to compress based on the vascular refill time, 
suggesting it is the better form of “smart” timing.  
The second study was used to develop a pulse sensor that could be used as the timing method 
for the compressions of the CGC device. The pulse sensor was designed with a unique calibration 
cycle to test all possible LED configurations to determine the configuration that would maximize 
the amplitude of the signal per individual. This calibration cycle was tested across a broad range 
of skin tones, as previously performance errors have been found with optical technology on darker 
skin tones [50], [51]. The sensor was able to measure the pulse signal on all participants. 
Additionally, all participants resulted in different optimal configurations from the calibration 
cycle; with the majority of the configurations composed of one or two LEDs. This result suggests 
that going forward the calibration cycle need only alternate through LED configurations with up 
to two LEDs lit, thereby drastically decreasing the time of the cycle. Furthermore, the shin was 
determined to be the location on the lower limb that both allowed for a low luminous intensity 
setting to be used on all participants, while also being the location that was the most resistant to 
movement of the three locations (shin, ankle, foot) tested. There is potential for the sensor to be 
used on the shin to trigger compressions; ideally after undergoing the calibration cycle in order to 
use the strongest pulse signal for timing the compressions.  
4.3 Thesis Limitations 
Limitations of the research are based primarily on the sample population used in the research 
of this thesis. 
 The hemodynamic results seen with the CGC device are limited to the responses of a young, 
healthy population. While the results between healthy and patient populations will share similar 
trends in response to IPC devices, the hemodynamic responses have been found to be greater with 
healthy individuals in comparison to patient populations [7], [64]. Tests should be done to 




The pulse sensor was similarly limited to testing only on a young, healthy population. Prior 
research has shown that in low perfusion conditions the PPG technology is more susceptible to 
performance errors, particularly in darker skin tones [50], [51]. Furthermore, both age and illness 
can impact the shape of the PPG waveform [43], which may impact the peak detection used to 
determine the pulse arrival in the lower limb. Research should be done on patient populations with 
broad ranges of skin tones and ages to further characterize the performance of the pulse sensor.  
4.4 Thesis Conclusions 
In conclusion, the new IPC device that used “smart” timing to apply compressions during the 
diastolic phase of the cardiac cycle results in an increase in stroke volume, muscle oxygenation, 
peripheral arterial velocity and peripheral venous displacement over an hour period in comparison 
to other commercial IPC devices with both fixed and “smart” timing. The pulse sensor has been 
proven to work effectively on the lower limb and may be able to further improve the hemodynamic 
response of the device if used to time the compressions. 
4.5 Future Work 
The pulse sensor has been shown to accurately measure the pulse signal in the lower limb. 
However, as seen in this study and other research, a key source of performance errors with PPG 
sensors is their sensitivity to motion corruption [47]–[49], [69], [79], [81]. The sensor’s sensitivity 
to motion may cause the sensor to be unreliable during the application of compressions, as the 
mechanical compressions will result in movement of the lower limb tissue. Additionally, because 
the noise generated from the compressions will be at the same frequency as the heart rate, due to 
the compressions being timed to the cardiac cycle, it will be much more difficult to isolate the 
pulse signal and filter out the noise. An investigation should be done to determine whether the 
pulse sensor can still accurately detect the pulse rate in the lower limb while compressions are 
taking place.  
It may be beneficially to determine if placing the sensor further from the site of compressions 
on the calf could lower the impact of compressions on the signal quality. This is supported by the 
trends seen both in this study and other PPG research which shows that as the sensors are moved 
further from the periphery of the limb (fingers or toes) the signal is less contaminated by movement 
noise [49]. Despite it being likely that the thigh would require a higher luminous intensity setting 
55 
 
in order to capture the pulse signal, due to absorption of the light by adipose tissue, it may be more 
resistant to motion artifacts caused by compressions. Therefore, measurement sites on the thigh 
should be investigated as a potential sensor sites during use of the IPC device. 
Another potential means of minimizing the effects of motion of the pulse signal would be to 
use multiple sensors. Previous use of multi-channel PPG sensors showed that the amount of motion 
corruption in the pulse signal of each channel during movement was different [69], [79]. As such 
it is possible that having multiple sensors could have a similar result and allow for the continuous 
determination of the sensor site with the best signal quality for the individual. 
The pulse sensor was designed with the goal of replacing the current timing mechanism for the 
compressions of the custom IPC device. Should the pulse sensor be able to measure the pulse 
reliable during compressions then work should be done to allow communication between the pulse 
sensor and the compression triggering software. The peripheral and systemic hemodynamic 
responses to the current method of timing should be compared to the responses if the pulse sensor 
was used as the timing mechanism. 
Pulse sensor could potentially be used as an assessment tool for local vasculature changes. As 
it is likely that vasculature conductance changes are occurring in the auxiliary vessels throughout 
compressions. Thereby the pulse sensor should be tested to see if it is able to detect the 
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